Sarfaraz Jasdanwala, MD
Addiction Medicine · Rolla, MONPI 1851646665
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 60.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $12,084 and has fallen 52.6% since, to $5,725 in 2025.
Across 47 payments — averaging $547.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$16K
- Gilead$10K
- Saol Therapeutics Inc.$260
- Exact Sciences$15
What the payments were for
- Consulting fees$6,09024%
- Speaking & faculty fees$13,58053%
- Travel & lodging$4,92619%
- Food & beverage$1,1134%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 25 | $15,653 |
| Gilead | 20 | $9,794 |
| Saol Therapeutics Inc. | 1 | $260 |
| Exact Sciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few addiction medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 16 | $26,475 |
| OzempicSemaglutide | 18 | $23,174 |
| TrulicityDulaglutide | 23 | $17,543 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 224 | $11,915 |
| Ondansetron Hcl | 97 | $7,879 |
| Acamprosate Calcium | 28 | $3,705 |
| Naltrexone Hcl | 63 | $2,951 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $1,940 |
| Bupropion XlBupropion Hcl | 74 | $1,093 |
| Baclofen | 116 | $1,041 |
| Hydroxyzine Pamoate | 125 | $958 |
| Trazodone Hcl | 101 | $892 |
| Olanzapine | 41 | $816 |
| Quetiapine Fumarate | 69 | $742 |
| Topiramate | 94 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $15,653 | $26,47516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in Missourion file to place this against a meaningful peer group, so we don't.
Other addiction medicine in Rolla
- Subbu SarmaLees Summit$150K
- Beenish ZaidiDittmer$12K
- Mehdi TajouriSpringfield$1K
- Shawn StranckmeyerSpringfield$974
- Jose Perez MartellKansas City$690
- Robert CorderSaint Joseph$636
- Rocksheng ZhongClinton$251
- Amanda HilmerSaint Louis$220
- Gary HammenKirkwood$188
- David SternbergLees Summit$93
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.